Long-term growth outcomes in children treated for chronic hepatitis C

J Pediatr. 2014 Dec;165(6):1252-4. doi: 10.1016/j.jpeds.2014.08.010. Epub 2014 Sep 17.

Abstract

Effects on linear growth were noted in children treated with peginterferon ± ribavirin in the Pediatric Study of Hepatitis C trial. Growth was further examined in a subset of patients followed for up to 6 years post-treatment. No long-term effects on height-for-age z scores were observed that could be attributed to hepatitis C virus treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Body Height / drug effects*
  • Child
  • Female
  • Follow-Up Studies
  • Growth / drug effects*
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon-alpha
  • Male
  • Polyethylene Glycols
  • Recombinant Proteins
  • Ribavirin / therapeutic use*

Substances

  • Antiviral Agents
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2a